Description: Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
Home Page: www.ipca.com
125, Kandivli Industrial Estate
Mumbai,
400067
India
Phone:
91 22 6210 5000
Officers
| Name | Title |
|---|---|
| Mr. Premchand Godha A.C. A., B. Com., CA | Executive Chairman |
| Mr. Pranay Premchand Godha | CEO, MD & Executive Director |
| Mr. Ajit Kumar Bhanwarlal Jain A.C.A., B.Sc. | CFO, MD & Executive Director |
| Mr. Harish Pandurang Kamath | Compliance Officer, Corporate Counsel & Company Secretary |
| Mr. Prashant Premchand Godha | Executive Director |
| Mr. Pawan Kothari | Vice President of Operations |
| Mr. Vishnu Saran Singh Kushwaha | Vice President of Technical |
| Mr. Sunil Ghai | President of Marketing |
| Mr. Sameer S. Tamhane | Senior Vice President of Human Resources |
| Dr. Ashok Kumar | President of R&D - Chemicals |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 62.8863 |
| Price-to-Book MRQ: | 5.8243 |
| Price-to-Sales TTM: | 4.7477 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 17335 |